Intech Investment Management LLC Has $14.47 Million Stock Holdings in Exelixis, Inc. $EXEL

Key Points

• Intech Investment Management LLC increased its stake in Exelixis, Inc. by 46.4%, owning approximately 0.14% of the company valued at $14.47 million.
• Exelixis reported $0.75 earnings per share for the last quarter, exceeding expectations, but experienced a 10.8% revenue decline year-over-year.
• Analysts have a consensus rating of "Moderate Buy" for Exelixis, with a target price averaging $44.06 per share.

Intech Investment Management LLC grew its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 46.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 392,022 shares of the biotechnology company's stock after purchasing an additional 124,297 shares during the quarter. Intech Investment Management LLC owned approximately 0.14% of Exelixis worth $14,473,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of EXEL. Bank of America Corp DE raised its position in shares of Exelixis by 7.6% in the fourth quarter. Bank of America Corp DE now owns 1,214,689 shares of the biotechnology company's stock valued at $40,449,000 after purchasing an additional 86,307 shares during the period. Balyasny Asset Management L.P. raised its position in shares of Exelixis by 1.9% in the fourth quarter. Balyasny Asset Management L.P. now owns 17,203 shares of the biotechnology company's stock valued at $573,000 after purchasing an additional 317 shares during the period. Captrust Financial Advisors raised its position in shares of Exelixis by 56.5% in the fourth quarter. Captrust Financial Advisors now owns 55,457 shares of the biotechnology company's stock valued at $1,847,000 after purchasing an additional 20,027 shares during the period. EP Wealth Advisors LLC increased its position in Exelixis by 11.8% during the fourth quarter. EP Wealth Advisors LLC now owns 13,194 shares of the biotechnology company's stock worth $439,000 after acquiring an additional 1,390 shares during the period. Finally, Graham Capital Management L.P. increased its position in Exelixis by 81.2% during the fourth quarter. Graham Capital Management L.P. now owns 19,821 shares of the biotechnology company's stock worth $660,000 after acquiring an additional 8,883 shares during the period. 85.27% of the stock is owned by institutional investors.

Exelixis Stock Performance

Shares of EXEL traded up $0.08 during mid-day trading on Friday, reaching $39.15. The company had a trading volume of 2,475,619 shares, compared to its average volume of 2,200,644. The company's 50 day simple moving average is $39.97 and its 200 day simple moving average is $39.64. Exelixis, Inc. has a 1-year low of $25.17 and a 1-year high of $49.62. The company has a market capitalization of $10.54 billion, a price-to-earnings ratio of 18.82, a P/E/G ratio of 0.81 and a beta of 0.32.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.63 by $0.12. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The company had revenue of $568.26 million for the quarter, compared to the consensus estimate of $574.36 million. During the same period last year, the company posted $0.84 EPS. The firm's quarterly revenue was down 10.8% compared to the same quarter last year. Exelixis has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on EXEL. Barclays raised their price target on shares of Exelixis from $29.00 to $40.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 10th. JMP Securities reissued a "market outperform" rating and issued a $50.00 target price on shares of Exelixis in a report on Tuesday, July 29th. Royal Bank Of Canada decreased their target price on shares of Exelixis from $50.00 to $45.00 and set a "sector perform" rating on the stock in a report on Tuesday, July 29th. William Blair reissued an "outperform" rating on shares of Exelixis in a report on Tuesday, July 29th. Finally, Morgan Stanley decreased their target price on shares of Exelixis from $48.00 to $46.00 and set an "overweight" rating on the stock in a report on Tuesday, July 29th. Thirteen equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $44.06.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.